Background: Inflammatory bowel disease (IBD) patients are at increased risk for venous thromboembolism (VTE) compared to the general population. Practice guidelines recommend pharmacologic prophylaxis for IBD inpatients. Aim: Our aim was to determine the rates of pharmacologic VTE prophylaxis in ulcerative colitis (UC) inpatients at a tertiary referral center. We also assessed potential predictors of pharmacologic prophylaxis. Methods: We conducted a retrospective cohort study of 377 UC patients between January 1st, 2007 and December 31st, 2011. The medical record of each patient was examined to determine whether pharmacologic VTE prophylaxis was ordered and administered. We conducted multiple logistic regression to determine predictors of pharmacologic prophylaxis. Results: The overall VTE pharmacologic prophylaxis rate was 67.6%. The rate of patients admitted to the medical service was 57.4% compared to 93.5% for those admitted to surgery. In medical patients who received pharmacologic VTE prophylaxis, 34.0% of ordered doses were not given compared to 17.4% of doses in surgical patients (P b 0.001). In the multiple logistic regression analysis, having an additional VTE risk factor (OR 2.46, 95% CI 1.41-4.30), extensive colitis (OR 2.26, 95% CI 1.32-3.87) or being admitted to a surgical service (OR 12.03, 95% CI 5.29-27.38) was associated with VTE pharmacologic prophylaxis. A v a i l a b l e o n l i n e a t w w w . s c i e n c e d i r e c t . c o m
Introduction
One of the most feared extraintestinal manifestations of inflammatory bowel disease (IBD) is the propensity to form pathologic thromboses, typically within the venous system. 1, 2 To date, several large European and North American studies have demonstrated an approximate two to three-fold increase in the risk of venous thromboembolism (VTE) in inflammatory bowel disease patients compared with controls. [3] [4] [5] [6] [7] Of note, hospitalized patients with ulcerative colitis (UC) may be at greatest risk. 6 Fortunately, VTE prophylaxis using heparin has been shown to be associated with a decrease in deep venous thrombosis (DVT), pulmonary embolism (PE) and mortality compared to placebo in at-risk medical inpatients. 8, 9 Given the efficacy of prophylactic anticoagulation, several practice guidelines recommend pharmacologic VTE prophylaxis for hospitalized IBD patients (Table 1) , particularly for those with UC. [10] [11] [12] [13] However, despite these recommendations it is unclear to what extent pharmacologic VTE prophylaxis measures are being employed in clinical practice. Published prophylaxis rates among at-risk hospitalized medical patients have ranged from 26.5% to 61.8%. [14] [15] [16] [17] Furthermore, studies have suggested that even when pharmacologic VTE prophylaxis is ordered for inpatients, it may not be for the appropriate dose or frequency. 18, 19 In patients admitted specifically with IBD, recent survey data suggests that rates of pharmacologic prophylaxis against DVT and PE may also be suboptimal. 20, 21 We hypothesized that in actual clinical practice, the use of pharmacologic prophylaxis to prevent VTE in patients with UC would be low.
Therefore, the goal of our study was to determine the rates of pharmacologic VTE prophylaxis in hospitalized patients with active ulcerative colitis at a tertiary referral center. We also examined several demographic, clinical and other factors to see whether any were associated with pharmacologic VTE prophylaxis use.
Methods

Data source
This was a retrospective cohort study of adult patients admitted to the Mount Sinai Medical Center (MSMC), NY, between January 1st 2007 and December 31st 2011. All patients admitted to the MSMC with an ICD-9 diagnosis of ulcerative colitis (556.x) were identified using the Mount Sinai Data Warehouse (MSDW), a Health Information Portability and Accountability Act (HIPAA) compliant clinical data source derived from both inpatient and outpatient care processes.
Eligibility criteria
The electronic medical record of each patient was examined closely to select only those patients whose primary reason for hospitalization was active ulcerative colitis (based on information extracted from the admission note and discharge summary). Patients with missing data were excluded. For patients with multiple hospitalizations, only data from their first admission was included in the analysis.
Data collection
Data collected included age, sex, race, insurance type, extent of colitis, length of hospital stay, admitting service (medical or surgical), admission route (via emergency room, directly admitted or outside hospital transfer), whether one or more orders were placed for pharmacologic VTE prophylaxis (yes/no), total number of doses ordered during the hospitalization, number of ordered doses received (as documented in the electronic medical record), type of pharmacologic prophylaxis used (dose and frequency), admission hemoglobin, and the presence of any additional VTE risk-factors (including history of VTE, known thrombophilia, 
Statistical analysis
Basic descriptive statistics were used and pharmacologic prophylaxis rates (based on whether at least one order was placed i.e. yes/no) were calculated overall and among various subgroups. In addition, the percentage of ordered pharmacologic prophylaxis doses that were actually received (documented in electronic medical record) was determined. Univariate analyses were performed using the chi-square (categorical variables) and Student's t-test (continuous variables) to evaluate the association between pharmacologic VTE prophylaxis and various patient and hospital-related factors. Multiple logistic regression was subsequently employed to assess whether variables (found to be significant at the 0.05 level in the univariate analysis) remained statistically significant when adjusted for other factors. All statistical analyses were carried out using Stata (version 12.1, StataCorp LLP, College Station, TX).
Ethical considerations
This study was approved by the Mount Sinai Medical Center Institutional Review Board.
Results
There were 377 patients eligible for the analysis. Selected patient characteristics for the study cohort are listed in Table 2 . There were 270 admitted to the medical service and 107 admitted to the surgical service. 52.6% were men, 78.8% were Caucasian, and their mean age was 38.0. Patients had an average length of stay of 9.0 days and a mean admission hemoglobin of 10.9.
Pharmacologic prophylaxis regimen
The majority of patients (76.5%) who received pharmacologic VTE prophylaxis were prescribed 5000 U of unfractionated heparin three times a day. 18.8% of patients were ordered for 5000 U of unfractionated heparin twice a day, while 4.3% received 40 mg (4000 International Units) of low molecular weight heparin daily.
Pharmacologic VTE prophylaxis orders
The percentage of all patients that had an order for pharmacologic VTE prophylaxis was 67.6%. The pharmacologic prophylaxis rate for patients admitted to the medical service was 57.4% compared to 93.5% for those admitted to surgery (P b 0.0001). The demographic and clinical characteristics of patients who did and did not have orders for pharmacologic VTE prophylaxis are shown in Table 2 . Patients who were ordered for pharmacologic prophylaxis were more likely to be admitted to the surgical service (42.3% vs. 5.6%, P b 0.001), possess one or more additional VTE risk factors (70.1% vs. 52.4%, P = 0.001), be hospitalized after 2009 (62.0% vs. 38.0%, P = 0.001) and have extensive colitis (67.5% vs. 52.4%, P b 0.001). Those who did not have pharmacologic VTE prophylaxis orders were more likely to be non-Caucasian (29.4% vs. 16.2%, P = 0.002) and have Medicare or Medicaid insurance (24.5% vs. 13.2%, P = 0.005). There was no significant difference in the ordering of pharmacologic VTE prophylaxis based on the route of patient admission (P = 0.235), need for blood transfusion (P = 0.440), age (P = 0.166), sex (P = 0.232) or admission hemoglobin (P = 0.506).
Pharmacologic prophylaxis received
The overall percentage of ordered doses of pharmacologic VTE prophylaxis that were actually received was 73.3%. Of the patients admitted to the medical service, 66.0% of ordered doses were received compared to 82.6% of those ordered for surgical patients (P b 0.001). 83.5% of all ordered doses of low molecular weight heparin were received Rates of pharmacologic VTE prophylaxis in hospitalized patients with active UC by patients compared with 81.8% (twice daily) and 71.7% (three times daily) of ordered doses of unfractionated heparin (P = 0.265). (Table 3) In the multiple logistic regression analysis, patients with one or more additional VTE risk factors (OR 2.46, 95% CI 1.41-4.30), those admitted to a surgical service (OR 12.03, 95% CI 5.29-27.38), patients hospitalized after 2009 (OR 2.60, 95% CI 1.54-4.37) and those with extensive colitis (OR 2.26, 95% CI 1.32-3.87) were more likely to have an order for pharmacologic VTE prophylaxis. Patients with Medicare or Medicaid insurance (OR 0.49, 95% CI 0.24-0.97) were less likely to have pharmacologic prophylaxis orders. There was no statistically significant association between being non-Caucasian and having an order for pharmacologic VTE prophylaxis after adjusting for other potential predictors (OR 0.67, 95% CI 0.36-1.26).
Predictors of VTE pharmacologic prophylaxis
Discussion
To our knowledge, this is the first study designed to explore actual rates of pharmacologic VTE prophylaxis in hospitalized UC patients. Our findings of an approximate 50% pharmacologic VTE prophylaxis rate in UC patients admitted to a medical service are close to recent cross-sectional survey estimates provided by gastroenterologists in the United States. 20 In this survey, only 43% of respondents, who practiced at an academic hospital, stated that they would give heparin to a hospitalized patient with severe UC. 20 Our results are also consistent with VTE prophylaxis rates reported in large multi-national studies of other at-risk medical inpatients. 14, 16 For patients admitted to the surgical service, the VTE pharmacologic prophylaxis rate in our study is also in line with published rates for various surgical inpatient groups. 22 Adjusting for other factors, patients admitted with UC to the surgical service were twelve times more likely to have an order for pharmacologic VTE prophylaxis compared to those admitted to medicine. Presumably, differences in rates between medical and surgical services can partly be explained by the knowledge that surgical patients are well known to be at high risk for VTE. Ordering and documentation of VTE prophylaxis may be a more recognized and widelyadopted standard of care for surgical providers and their trainees.
There are several reasons specific to IBD that may result in low rates of pharmacologic VTE prophylaxis in UC patients admitted to the medical service. One possibility is a lack of awareness of the inherent risk of VTE in the IBD population or knowledge of existing guidelines addressing pharmacologic prophylaxis. In a recent survey by Sam and colleagues, over 50% of gastroenterologists reported that they were unaware of any published guidelines for VTE prophylaxis in hospitalized IBD patients. 21 In an earlier study by our group, approximately 20% of respondents did not believe that patients admitted with IBD have a high risk of VTE. 14 Another factor that may influence a provider's decision to order pharmacologic VTE prophylaxis (or hold doses even when a patient has an active order) is the presence of rectal bleeding. However, outside of the setting of massive gastrointestinal hemorrhage with hemodynamic instability, heparin appears to be safe. This is supported by the lack of bleeding complications observed in several studies when heparin (at higher doses than for VTE prophylaxis) was given to steroid-refractory UC patients as actual treatment for their disease. 23, 24 Unnecessarily avoiding or withholding pharmacologic prophylaxis may have life-threatening consequences if a patient develops a PE and should not represent a contraindication to its use.
One of the most interesting and unexpected findings from our study is that one third of ordered doses of prophylactic anticoagulation against VTE were not ultimately given to medical service patients. If true and replicated in other studies, this is extremely concerning and might have major ramifications for future quality improvement projects. If doses are missed (patient off the floor for a procedure or test, patient refusing doses due to concerns over injection-site discomfort etc.) or held, (patient having rectal bleeding) then even with an active order, patients may still be at risk for VTE. In our study, patients ordered for daily low molecular heparin A. Tinsley et al.
missed less doses than those placed on unfractionated heparin (requiring twice daily or three times daily dosing). Therefore, for most patients, daily dosing with a low molecular form of heparin in hospitalized IBD patients may be the preferred choice. It is worth noting that low molecular weight heparin appears to be used much less frequently overall in the United States compared to other countries. 17 Our results revealed other factors, in addition to being admitted to the surgical service, that were independently associated with having pharmacologic VTE prophylaxis ordered. Patients with an additional risk factor for a venous thromboembolic event were twice as likely to have prophylactic anticoagulation ordered after adjusting for other factors. One possible explanation is that some providers may be more willing to order heparin only when they perceive a more favorable risk-benefit profile for a patient. Compared to left-sided only disease, patients with extensive colitis were also twice as likely to have an order for pharmacologic VTE prophylaxis. Extensive disease involvement may lead to greater symptoms, diminished ability to ambulate and alert providers of the increased risk of DVT and PE. Finally, patients hospitalized in the final two years of the study cohort were significantly more likely to have pharmacologic prophylaxis ordered. This finding may partly reflect increased provider awareness in recent years of the importance of pharmacologic VTE prophylaxis. Of note, the American College of Gastroenterology UC practice guidelines first recommended prophylactic heparin be given to hospitalized patients in early 2010. 10 Interestingly, patients with Medicare and Medicaid insurance were less likely to have pharmacologic VTE prophylaxis ordered. While the reason for this finding remains unclear, it is somewhat intriguing that this same factor has been shown to be independently associated with VTE. 5 Clearly, further investigation is needed to determine whether these patients are somehow under-protected with respect to VTE prophylaxis.
There are several limitations worth noting regarding our study. Our data originates from a single tertiary care center with considerable experience in caring for patients with IBD. Therefore, our pharmacologic VTE prophylaxis rates and study results may not be generalizable to other centers that may well differ with respect to provider practice patterns and hospital systems. In addition, the retrospective nature of our study design also imparts several specific limitations. These limitations include the inability to reliably capture the number of bloody bowel movements on admission for each patient. The impact of rectal bleeding on the ordering and administration of pharmacologic prophylaxis could not therefore be adequately assessed. However, we did adjust our results for admission hemoglobin level and need for blood transfusion with neither of these factors found to be associated with pharmacologic VTE prophylaxis. We were also unable to compare possible bleeding complications that occurred in patients who received pharmacologic VTE prophylaxis. Finally, the use of mechanical VTE prophylaxis could not be captured accurately in our study. While this is unfortunate, recommendations in IBD societal guidelines do focus on pharmacologic prophylaxis, as mechanical methods do not appear to reduce rates of PE or decrease mortality.
Overall, this study highlights an extremely important aspect of inpatient IBD care that appears to be in significant need of quality improvement. If our pharmacologic prophylaxis rates are even close to representative of other centers across the US, then patients with UC may be at significant risk of a potentially deadly disease-related complication. Future quality improvement initiatives should not only look to increase the VTE pharmacologic prophylaxis rates but also adopt strategies that guarantee that doses are not missed or held inappropriately. Furthermore, there is clearly a continued need to educate providers and disseminate best practices. By ensuring that IBD patients are adequately protected throughout their hospitalization, unnecessary morbidity and mortality may be prevented.
